DDInter286 DDInter808
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
Garlic allergenic extract is used in allergenic testing.
Caplacizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Caplacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Caplacizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Caplacizumab {u} may lead to a major life threatening interaction when taken with {v} Acetylsalicylic acid
Caplacizumab {u} may lead to a major life threatening interaction when taken with {v} Prasugrel
Caplacizumab may cause a minor interaction that can limit clinical effects when taken with Turmeric
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Caplacizumab may lead to a major life threatening interaction when taken with Acetylsalicylic acid
Caplacizumab may lead to a major life threatening interaction when taken with Prasugrel